Influenza Drug Market Struggles with Reimbursement Issues and Pandemic Fears

Roche's Tamiflu Dominates a Market Driven by Speculation, According to a

New Study from Decision Resources

Apr 18, 2006, 01:00 ET from Decision Resources, Inc.

    WALTHAM, Mass., April 18 /PRNewswire/ -- Decision Resources, Inc., one
 of the world's leading research and advisory firms focusing on
 pharmaceutical and healthcare issues, finds that the influenza therapeutic
 drug market is constrained by reimbursement, formulary hurdles, and
 perceptions of low efficacy of current antivirals. However fears of a
 future influenza pandemic are driving sales. According to the now available
 Influenza -- Payer Constraints and Pandemic Fears report, although recent
 concern over the health impact of an influenza pandemic had increased
 stockpiling of influenza antivirals in all markets, overall use of
 influenza antiviral drugs remains low owing to their high cost,
 inconvenience, and perceived lack of efficacy.
     Reimbursement is a hurdle for the influenza drug market as well.
     "Despite having failed to achieve reimbursement status in many European
 Union markets, Roche's Tamiflu is the overwhelmingly dominant product in
 the market. However, future entrants to this market must demonstrate
 convincing cost-benefit data to gain favorable reimbursement and widespread
 usage," said Aaron Woolsey, analyst at Decision Resources.
     About Influenza -- Payer Constraints and Pandemic Fears from Decision
     Influenza -- Payer Constraints and Pandemic Fears covers the current
 state of the influenza drug market. The report includes:
     * Analysis of the influenza market driven by qualitative interviews with
       KOLs and survey data from high prescribing physicians defining their
       target product profile.
     * Assessment of the influenza market including diagnosed and drug-treated
       populations, patient share/market share projections, cost per day and
       compliance estimates.
     * Discussion of the opportunity for drug developers given the market's
       relatively large, seasonal patient population, limited efficacy of
       current therapies and heightened concerns over influenza epidemic.
     * Examination of payer reluctance to reimburse antivirals for influenza
       and the reimbursement outlook for drugs with improved efficacy.
     The report can be purchased by contacting Decision Resources. Members
 of the media may request a complimentary copy.
     About Decision Resources
     Decision Resources, Inc., ( is a world
 leader in market research publications, advisory services, and consulting
 designed to help clients shape strategy, allocate resources, and master
 their chosen markets.
     All company, brand, or product names contained in this document may be
 trademarks or registered trademarks of their respective holders.
     For more information, contact:
      Elizabeth Marshall
      Decision Resources, Inc.

SOURCE Decision Resources, Inc.